# Genetic Testing Company Partnerships

**Document Version**: 1.0
**Last Updated**: November 8, 2025
**Owner**: Chief Medical Officer & Chief Development Officer
**Purpose**: Strategy for partnering with genetic testing companies to dramatically increase AATD diagnosis rates through direct-to-consumer testing, physician-ordered clinical testing, and data mining of existing genomic databases

---

## ðŸ“‹ Table of Contents

1. [The Diagnosis Crisis](#the-diagnosis-crisis)
2. [Partnership Opportunities](#partnership-opportunities)
3. [Target Companies](#target-companies)
4. [Partnership Models](#partnership-models)
5. [Data Mining Partnerships](#data-mining-partnerships)
6. [Clinical Testing Partnerships](#clinical-testing-partnerships)
7. [At-Home Testing Programs](#at-home-testing-programs)
8. [Cascade Screening Strategy](#cascade-screening-strategy)
9. [Economics & ROI](#economics-roi)
10. [Implementation Roadmap](#implementation-roadmap)

---

## The Diagnosis Crisis

### Only 10% of AATD Patients Are Diagnosed

**The Numbers**:

- **Estimated US AATD patients**: 100,000-200,000 (based on carrier frequency + population genetics)
- **Actually diagnosed**: 10,000-20,000 (10% detection rateâ€”90% undiagnosed)
- **Receiving treatment**: 5,000-8,000 (50-80% of diagnosedâ€”many diagnosed but not treated)

**Why So Few Diagnosed?**:

1. **Physicians don't test** (primary care doctors don't think of AATDâ€”rare disease, not on radar)
2. **Misdiagnosed as COPD/asthma** (symptoms identicalâ€”patients treated for "regular" COPD, underlying genetic cause missed)
3. **Testing barriers** (requires blood draw + send to labâ€”patients/doctors skip due to hassle)
4. **Lack of awareness** (patients don't know AATD existsâ€”never ask to be tested)

---

### The Opportunity: Genetic Testing Can 10x Diagnosis Rates

**Traditional Testing** (current state):

- Patient sees pulmonologist for COPD symptoms
- Doctor orders AAT level blood test (measures protein levelâ€”if low, suggests AATD)
- If low, doctor orders genetic test (confirms which AATD mutationsâ€”Pi*ZZ, Pi*SZ, etc.)
- **Bottleneck**: Requires symptomatic patient + aware physician (most patients/doctors never reach this point)

**Genetic-First Approach** (new paradigm):

- Patient takes genetic test for ANY reason (ancestry, health screening, cancer riskâ€”23andMe, Invitae, etc.)
- Test includes SERPINA1 gene (AAT geneâ€”AATD mutations visible in genetic data)
- If AATD mutations detected, patient notified + referred to specialist
- **Advantage**: Catches patients BEFORE symptoms (test for other reasons, AATD found incidentallyâ€”10x-100x more patients identified)

**Potential Impact**:

- 30 million Americans have taken 23andMe test (if AATD check includedâ€”could identify 30,000-60,000 undiagnosed patients overnight)
- 5 million clinical genetic tests ordered annually (cancer, prenatal, rare diseaseâ€”if AATD checked on allâ€”identify 5,000-10,000 new patients/year)

**This is the Foundation's #1 diagnosis strategy.**

---

## Partnership Opportunities

### Three Partnership Tracks

**Track 1: Consumer Genomics Companies** (23andMe, AncestryDNA)

- **Goal**: Mine existing databases (identify AATD patients who already tested, notify them)
- **Target companies**: 23andMe (30M customers), AncestryDNA (20M), MyHeritage (5M)
- **Impact**: 55,000 databases = 5,500-11,000 AATD patients (1 in 5,000 - 1 in 10,000 prevalence)â€”largest untapped reservoir

---

**Track 2: Clinical Genetic Testing Companies** (Invitae, GeneDx, Myriad)

- **Goal**: Add AATD to standard testing panels (any patient getting genetic test = automatically screened for AATD)
- **Target companies**: Invitae (5M tests/year), GeneDx (rare disease focus), Myriad (hereditary cancer)
- **Impact**: 5M tests/year Ã— 0.1% AATD prevalence = 5,000 new diagnoses/year

---

**Track 3: Physician-Ordered Diagnostic Labs** (Quest, LabCorp, Mayo)

- **Goal**: Simplify AATD testing for physicians (make ordering easyâ€”single checkbox, insurance-covered)
- **Target companies**: Quest Diagnostics, LabCorp, Mayo Medical Labs
- **Impact**: 100,000 physicians order tests more frequently (simple, affordableâ€”double testing rate = 2,000-5,000 new diagnoses/year)

---

## Target Companies

### Tier 1: Consumer Genomics (Highest Impact)

**1. 23andMe**

- **Database**: 30 million customers (largest consumer genomics databaseâ€”tested for ancestry, health reports)
- **Current AATD Coverage**: PARTIAL (23andMe health reports include "Alpha-1 Carrier Status" for 23andMe+ subscribersâ€”identifies carriers [Pi*MZ, Pi*MS], but not comprehensive [misses many mutations])
- **Opportunity**: COMPREHENSIVE AATD CHECK (scan for all SERPINA1 mutationsâ€”Pi*ZZ, Pi*SZ, rare variants, not just common carriers)

**Partnership Approach**:

1. **Data mining retrospective** (23andMe analyzes existing 30M customer data for AATD mutationsâ€”estimate 30,000-60,000 AATD patients in database)
2. **Customer notification** (23andMe emails customers with AATD mutationsâ€”"Your genetic data shows Alpha-1, here's what it means," link to Foundation resources)
3. **Clinical confirmation** (Foundation coordinates follow-up testingâ€”phenotype [AAT level] + genotype confirmation, connect to specialist)
4. **Ongoing prospective** (all new 23andMe customers automatically checked for AATDâ€”embedded in health reports)

**Business Model**:

- **For 23andMe**: Differentiator (only consumer test that comprehensively checks AATDâ€”attracts customers with family history, lung disease), Value-add to subscribers (23andMe+ health reports justify $199/yearâ€”AATD check adds value)
- **For Foundation**: Data goldmine (identify tens of thousands undiagnosedâ€”largest single diagnosis source), Credibility (partner with leading consumer genomics companyâ€”raises Foundation profile)

**Revenue Potential for Foundation**:

- 23andMe pays Foundation consulting fee: $100K-$300K/year (Foundation provides clinical expertiseâ€”interpretation guidelines, patient resources)
- Foundation offers clinical confirmation testing: $200-$500/patient Ã— 5,000 patients/year = $1M-$2.5M (Foundation subsidizes for uninsuredâ€”net cost, but worth it for diagnosis impact)

---

**2. AncestryDNA**

- **Database**: 20 million customers (second-largest consumer genomicsâ€”ancestry focus, not health reports currently)
- **Current AATD Coverage**: NONE (AncestryDNA ancestry-onlyâ€”doesn't provide health reports, genetic data not interpreted for disease risk)
- **Opportunity**: HEALTH EXPANSION (AncestryDNA exploring health reportsâ€”AATD could be pilot condition)

**Partnership Approach**:

1. **Pilot AATD health report** (Foundation + AncestryDNA co-develop first health reportâ€”"Your Alpha-1 Status," test market before full health platform)
2. **Cross-sell to existing customers** (20M customers can unlock AATD report for $49â€”AncestryDNA revenue, Foundation gains diagnoses)

**Business Model**:

- **For AncestryDNA**: Health entry (AATD = low-risk pilot [not cancer/Alzheimer'sâ€”less controversy], proven demand [100K AATD families want answers], test waters for broader health expansion)
- **For Foundation**: Second-largest database (20M customersâ€”potential 20,000-40,000 AATD patients)

---

**3. MyHeritage DNA, LivingDNA (Tier 3 Consumer)**

- **Databases**: 5M customers (MyHeritage), 1M (LivingDNA)â€”smaller but still valuable
- **Approach**: Same as 23andMe/Ancestry (data mining + ongoing prospective testing)
- **Impact**: 6M databases = 600-1,200 AATD patients

---

### Tier 2: Clinical Genetic Testing (High Impact, Medical Setting)

**4. Invitae**

- **Testing Volume**: 5 million clinical tests/year (physician-orderedâ€”cancer, prenatal, rare disease panels)
- **Current AATD Coverage**: PARTIAL (Invitae's "Pulmonary Panel" includes SERPINA1â€”but only ordered for symptomatic patients, not broad)
- **Opportunity**: ADD AATD TO ALL PANELS (cancer panel, cardiac panel, prenatalâ€”any test includes SERPINA1 check)

**Partnership Approach**:

1. **Expand SERPINA1 coverage** (add to all multi-gene panelsâ€”~100 genes per panel, adding SERPINA1 = marginal cost [already sequencing exome, just report another gene])
2. **Clinical interpretation** (Foundation provides interpretation guidelinesâ€”help physicians understand results, recommendations)
3. **Patient follow-up** (Invitae refers AATD-positive patients to Foundationâ€”connect to care, enroll in registry)

**Business Model**:

- **For Invitae**: Comprehensive testing (market as "most complete genetic test"â€”includes AATD, competitors may not), Partnership differentiation (only lab partnered with AATD Foundationâ€”credibility)
- **For Foundation**: 5M tests/year Ã— 0.1% = 5,000 new diagnoses/year (largest annual diagnosis source)

**Cost**:

- Foundation pays Invitae: $0 (SERPINA1 already in many panelsâ€”no additional cost to add to all panels)
- Foundation provides interpretation support: $100K-$200K/year (staff timeâ€”genetic counselor, educational materials)

---

**5. GeneDx (Rare Disease Focus)**

- **Testing Volume**: 500,000 tests/year (smaller than Invitae, but rare disease specialtyâ€”higher AATD hit rate)
- **Opportunity**: REFLEX TESTING (if patient has unexplained liver disease or early COPDâ€”automatically add AATD test without physician re-ordering)

**Partnership Approach**:

- GeneDx builds AATD into reflex protocol (liver panel ordered + elevated transaminases + age <50 = automatic SERPINA1 check)
- Foundation provides clinical decision support (which scenarios warrant AATD testingâ€”codify into GeneDx ordering system)

---

**6. Myriad Genetics (Cancer Focus)**

- **Testing Volume**: 1 million tests/year (hereditary cancerâ€”BRCA, Lynch, etc.)
- **Opportunity**: INCIDENTAL FINDING (cancer panel patients = exome sequenced, AATD visible as incidental finding)

**Partnership Approach**:

- Myriad reports AATD as "additional finding" (currently report secondary findings per ACMG guidelines [heart, cancer]â€”add AATD to list)
- Foundation becomes referral partner (Myriad patients with AATD â†’ Foundation connects to pulmonologist)

---

### Tier 3: Diagnostic Labs (Clinical Access)

**7. Quest Diagnostics**

- **Market Position**: Largest US lab (2,500 patient service centers, 150M patient encounters/yearâ€”ubiquitous)
- **Current AATD Testing**: Available but underutilized (physicians can order SERPINA1 genotypingâ€”but few know to order, complex test codes)
- **Opportunity**: SIMPLIFY ORDERING (make AATD testing one-clickâ€”pre-built order set, insurance pre-authorization support)

**Partnership Approach**:

1. **Develop "AATD Diagnostic Workup" order set** (Quest EMR integrationâ€”physician checks one box, Quest runs AAT level + genotype + phenotype, comprehensive report)
2. **Insurance navigation** (Quest pre-verifies coverageâ€”tells physician if covered before ordering, reduces physician hesitation)
3. **Foundation co-marketing** (Foundation educates physiciansâ€”"Test for AATD using Quest's simple order set," Quest logo on Foundation materials, mutual benefit)

**Impact**:

- Currently ~5,000 AATD tests ordered through Quest/year (estimatedâ€”physicians who know to order)
- Simplified ordering could double: 10,000 tests/year Ã— 15% positive rate = 1,500 new diagnoses/year

---

**8. LabCorp**

- **Market Position**: Second-largest US lab (similar to Questâ€”1,900 patient service centers, 100M encounters/year)
- **Approach**: Same as Quest (simplify ordering, insurance navigation, co-marketing)

---

**9. Mayo Medical Laboratories**

- **Market Position**: Boutique lab (high-complexity testingâ€”physicians order Mayo for esoteric tests)
- **Current AATD Testing**: Gold standard (Mayo runs most comprehensive SERPINA1 sequencingâ€”detects rare variants)
- **Opportunity**: RARE VARIANT PARTNERSHIP (Foundation funds Mayo to build rare variant databaseâ€”identify novel AATD mutations, improve diagnostics)

**Partnership Approach**:

- Foundation funds Mayo research: $100K-$200K/year (sequence 1,000 AATD patientsâ€”identify rare/novel SERPINA1 variants)
- Mayo shares data with Foundation (Foundation registry gains genetic dataâ€”research resource)

---

## Partnership Models

### Model 1: Data Mining (23andMe, AncestryDNA)

**How It Works**:

1. **Foundation requests analysis** (asks 23andMe: "Scan your database for all SERPINA1 mutations, tell us how many AATD patients you have")
2. **Company analyzes retrospectively** (23andMe runs bioinformatics on 30M genomesâ€”identify Pi*ZZ, Pi*SZ, rare variants)
3. **Company notifies customers** (23andMe emails: "Your genetic data shows Alpha-1 Antitrypsin Deficiency, click here to learn more")
4. **Foundation provides resources** (landing pageâ€”"What is AATD?", find a doctor, confirm diagnosis, enroll in registry)

**Legal/Ethical Considerations**:

- âœ… **Customer consent** (23andMe Terms of Service allow health reportsâ€”customers opted in)
- âœ… **Validated findings** (SERPINA1 variants well-establishedâ€”not experimental, clinically actionable)
- âš ï¸ **Psychological impact** (unexpected diagnosisâ€”some customers anxious, Foundation must provide support)

**Revenue Model**:

- Foundation pays 23andMe: $0 (23andMe benefits from value-addâ€”no fee)
- OR 23andMe pays Foundation: $100K-$500K (Foundation provides clinical interpretationâ€”consulting fee)
- Foundation offers clinical confirmation: $200-$500/patient (phenotype testing, genetic counselingâ€”Foundation subsidizes for low-income)

---

### Model 2: Add AATD to Existing Panels (Invitae, GeneDx)

**How It Works**:

1. **Foundation negotiates with lab** (Invitae: "Add SERPINA1 to all your multi-gene panelsâ€”marginal cost near-zero, diagnoses high-impact")
2. **Lab updates panels** (next software updateâ€”SERPINA1 included, all future tests check for AATD)
3. **Lab reports AATD findings** (physician orders cancer panelâ€”report includes "SERPINA1: Pi\*MZ [carrier], recommend follow-up")
4. **Lab refers to Foundation** (report includes: "For AATD resources, visit MarkEglyFoundation.org")

**Legal/Ethical Considerations**:

- âœ… **Informed consent** (patients consented to genetic testingâ€”AATD included in test, not separate consent needed)
- âœ… **Clinical utility** (AATD is medically actionableâ€”not incidental finding of unclear significance)
- âš ï¸ **Physician education** (primary care doctors may not know AATDâ€”Foundation must educate or provide specialist referrals)

**Revenue Model**:

- Foundation pays lab: $0 (Invitae adds SERPINA1 for freeâ€”marginal cost negligible)
- Foundation provides support: $100K-$200K/year (genetic counselor, physician education materialsâ€”Foundation's cost)

---

### Model 3: Subsidized At-Home Testing (Foundation-Funded Program)

**How It Works**:

1. **Foundation partners with lab** (e.g., Invitae, Fulgentâ€”negotiate bulk pricing for AATD-only test)
2. **Foundation offers free/low-cost kits** (website: "Get tested for AATDâ€”$25 at-home kit," Foundation subsidizes remaining $75-$175)
3. **Patient orders, receives kit** (mail-deliveredâ€”swab cheek, mail back, results in 2-3 weeks)
4. **Positive results = Foundation follow-up** (genetic counseling, connect to specialist, enroll in registry)

**Target Audiences**:

- **Family members of diagnosed patients** (cascade screeningâ€”first-degree relatives have 50% carrier risk, 25% affected risk if both parents carriers)
- **At-risk populations** (ancestry: Northern European, especially Scandinavianâ€”higher carrier rates, South/East Asian much lower)
- **Symptomatic but undiagnosed** (early COPD, unexplained liver diseaseâ€”physicians didn't test, patient self-refers)

**Economics**:

- Lab cost per test: $100-$200 (SERPINA1 sequencing + interpretation)
- Foundation subsidizes: $75-$175/test (patient pays $25, Foundation pays rest)
- If 5,000 people order/year: $375K-$875K annual cost (Foundation budget line item)
- Diagnostic yield: 15-20% positive (family members higher, general population lowerâ€”average 15%)
- Cost per diagnosis: $500-$1,167 (reasonableâ€”compares favorably to $5K-$10K cost of symptomatic patient diagnosis via traditional route)

---

### Model 4: Reflex Testing (Quest, LabCorp)

**How It Works**:

1. **Foundation + lab develop reflex protocol** (if patient has AAT level <100 mg/dL [low]â€”automatically run genotype, physician doesn't need to re-order)
2. **Lab implements in LIS** (laboratory information systemâ€”built-in logic: low AAT â†’ trigger genotype)
3. **Physician receives complete workup** (orders AAT levelâ€”gets level + genotype + interpretation, one-stop diagnosis)

**Why Reflex Testing Matters**:

- Currently: Physician orders AAT level â†’ result comes back low â†’ physician must remember to order follow-up genotype (50% forget, patient lost to follow-up)
- With reflex: Physician orders AAT level â†’ lab automatically runs genotype â†’ physician receives complete diagnosis (100% follow-through)

**Negotiation**:

- Foundation pays lab: $0 (reflex testing is standard practiceâ€”no additional cost)
- Foundation provides interpretation guidelines: $50K-$100K one-time (develop clinical decision supportâ€”when to reflex, how to report)

---

## Data Mining Partnerships

### 23andMe Partnership Deep Dive (Highest Priority)

**Phase 1: Proof of Concept** (Months 1-6, $50K-$100K)

**Step 1: Foundation Initiates Discussion**

- Foundation reaches out to 23andMe Research team (collaborations@23andme.comâ€”they partner with disease foundations regularly)
- Proposal: "Foundation wants to identify undiagnosed AATD patients in 23andMe databaseâ€”mutual benefit (23andMe adds value to customers, Foundation finds patients)"

**Step 2: 23andMe Analyzes Data**

- 23andMe runs bioinformatics query (scan 30M customer genomes for SERPINA1 variantsâ€”Pi*ZZ, Pi*SZ, Pi\*Z null, rare variants)
- Expected findings: 30,000-60,000 AATD patients (1 in 500 - 1 in 1,000 prevalenceâ€”depends on definitions, severity cutoffs)

**Step 3: Pilot Notification** (100-500 customers)

- 23andMe emails subset of AATD-positive customers (test messagingâ€”"Your genetic data shows Alpha-1, new finding available in your 23andMe account")
- Foundation provides landing page (education, resources, find specialist, confirm diagnosis)
- Measure response rate (how many click through, how many confirm diagnosis, how many enroll in Foundation registry)

**Success Metrics for Pilot**:

- Click-through rate: 30-50% (of emailed customers click to learn moreâ€”indicates interest)
- Confirmation rate: 10-20% (of clicked, complete clinical confirmationâ€”some ignore, some already diagnosed)
- Registry enrollment: 50-70% (of confirmed, enroll in Foundation registryâ€”research participation)

---

**Phase 2: Full Rollout** (Months 7-12, $200K-$500K)

**If Pilot Successful**:

- 23andMe emails all AATD-positive customers (30,000-60,000 customersâ€”largest AATD diagnosis event in history)
- Foundation prepares infrastructure (genetic counselors answer questions, specialist network ready, website scaled for traffic)

**Operational Requirements**:

- **Genetic counseling**: 5-10 FTEs (handle inquiriesâ€”"What does Pi\*MZ mean?", "Should I see a doctor?", 30,000 customers Ã— 10% call = 3,000 calls, 20 calls/day/counselor = 150 counselor-days, 5 FTEs for 6 months)
- **Specialist network**: 200+ pulmonologists trained (accept Foundation referralsâ€”23andMe customers in every state, need nationwide coverage)
- **Website infrastructure**: Scale to 100K visitors/month (currently 5Kâ€”20x increase, ensure doesn't crash)

**Cost**:

- Genetic counselors: $200K (5 FTEs Ã— 6 months Ã— $8K/month)
- Specialist network development: $100K (training materials, recruiter time, 1 year advance work)
- Website scaling: $50K (cloud hosting, CDN, load testing)
- Marketing/PR: $50K (press release, media outreachâ€”"23andMe + Mark Egly Foundation Identify Tens of Thousands with Rare Disease")
- **Total**: $400K (one-time costâ€”but identifies 30,000 patients, $13/patientâ€”incredibly cost-effective)

---

**Phase 3: Ongoing Prospective** (Year 2+, $50K-$100K/year)

**All New 23andMe Customers Automatically Checked**:

- 23andMe adds AATD to standard health reports (new customer tests for ancestryâ€”automatically receives AATD check as part of 23andMe+ subscription)
- 2 million new customers/year Ã— 0.1% AATD = 2,000 new diagnoses/year (ongoing annual identificationâ€”sustainable pipeline)

**Foundation's Role**:

- Maintain landing page (update resources, specialist directoryâ€”annual refresh)
- Answer inquiries (1-2 FTEs ongoingâ€”handle 2,000 new notifications/year)
- Annual data review (23andMe shares aggregate dataâ€”how many diagnosed, demographics, outcomesâ€”research insights)

**Cost**: $50K-$100K/year ongoing (1-2 FTE + infrastructureâ€”permanent budget line item)

---

## Clinical Testing Partnerships

### Invitae Partnership Deep Dive

**Goal**: Add SERPINA1 to All Invitae Panels (5M tests/year = 5,000 new diagnoses/year)

**Phase 1: Negotiation** (Months 1-6)

**Foundation's Pitch to Invitae**:

1. **Clinical utility** (AATD is medically actionableâ€”early diagnosis prevents lung damage, liver monitoring, family cascade screening)
2. **Low cost** (Invitae already sequences exomesâ€”adding SERPINA1 to report = marginal cost near-zero, already in data)
3. **Differentiation** (Invitae can market as "most comprehensive genetic test"â€”includes AATD, competitors may not)
4. **Partnership visibility** (Foundation promotes Invitae to physiciansâ€”"We recommend Invitae for AATD testing," co-marketing)

**Invitae's Concerns**:

- â“ **Physician confusion** (primary care doctors don't know AATDâ€”will ignore findings, waste money to report something not acted on)
- â“ **Insurance coverage** (payers may deny if AATD not primary indicationâ€”e.g., cancer panel, AATD incidental, payer refuses to pay)

**Foundation's Solutions**:

- âœ… **Physician education** (Foundation develops CME courseâ€”"What to Do with an AATD Result," train 5,000 physicians, ensure findings acted on)
- âœ… **Specialist referral network** (Foundation provides pulmonologist directoryâ€”primary care can refer, don't need to manage themselves)
- âœ… **Insurance advocacy** (Foundation works with payersâ€”argue AATD reporting is standard of care, should be covered on any genetic test)

---

**Phase 2: Implementation** (Months 7-12)

**Invitae Adds SERPINA1 to Panels**:

- Software update (next panel versionâ€”all multi-gene panels include SERPINA1 in report)
- Clinician notification (Invitae emails ordering physiciansâ€”"Update: All panels now include SERPINA1 [Alpha-1], see educational resources at MarkEglyFoundation.org")

**Foundation Delivers Support**:

- CME course: "Interpreting AATD Genetic Results" (1-hour online module, 1.0 CME credit, educate 5,000 physicians Year 1)
- Specialist directory: 200+ pulmonologists (accept referralsâ€”nationwide coverage, primary care can refer AATD-positive patients)
- Patient resources: Updated website (FAQ, "I received an AATD result, now what?", connect to Foundation services)

---

**Phase 3: Ongoing Stewardship** (Year 2+)

**Annual Review**:

- Invitae shares data: # of AATD findings/year (e.g., 5,000), variant distribution (Pi*ZZ, Pi*SZ, carriers), physician response (how many referred to specialists)
- Foundation analyzes: Which findings most actionable? (Pi*ZZ always referred, Pi*MZ [carrier] often ignoredâ€”focus education on carrier management)
- Optimize: Improve physician education (Year 2â€”add case studies, decision algorithms, increase referral rate)

---

## At-Home Testing Programs

### Foundation-Funded Cascade Screening

**Goal**: Test First-Degree Relatives of Diagnosed Patients (Highest-Yield Population)

**Why Family Members?**

- **Genetics**: If parent has Pi*ZZ AATDâ€”children have 50% chance of inheriting one Z allele (carrier), 0% chance of Pi*ZZ (unless other parent also carrier)
- **If both parents carriers (Pi*MZ Ã— Pi*MZ)**: Children have 25% chance Pi*ZZ (affected), 50% chance Pi*MZ (carrier), 25% chance Pi\*MM (normal)
- **First-degree relatives of Pi\*ZZ patients**: Siblings have 25% chance Pi\*ZZ, 50% chance carrier (high yieldâ€”1 in 4 affected)

**Cascade Screening Process**:

1. **Index patient diagnosed** (patient learns they have Pi\*ZZ AATDâ€”first in family to be diagnosed)
2. **Foundation encourages family testing** (genetic counselor: "Your siblings have 25% chance of AATD, we recommend testing," mail 5 free test kitsâ€”one for each sibling, parents)
3. **Family members order kits** (mail-in cheek swabâ€”Invitae or Fulgent, Foundation pays $100-$200/kit)
4. **Results return** (2-3 weeksâ€”positive results trigger genetic counseling + specialist referral)

**Expected Yield**:

- Index patient has average 2 siblings (US family sizeâ€”some more, some fewer)
- 2 siblings Ã— 25% affected = 0.5 additional diagnoses per index patient
- If Foundation diagnoses 1,000 new index patients/year (through other programs)â€”cascade screening finds 500 additional (50% increaseâ€”cascade amplifies every diagnosis strategy)

**Economics**:

- Cost per kit: $100-$200 (Foundation subsidizesâ€”family free)
- Kits per index patient: 5 (2 siblings, 2 parents, 1 spouse [if children]â€”cast wide net)
- Cost per index patient: $500-$1,000 (5 kitsâ€”not all will test, but offer to all)
- Index patients/year: 1,000 (Foundation diagnoses via other programsâ€”23andMe, Invitae, etc.)
- **Total cascade screening budget**: $500K-$1M/year (finds 500 additional patientsâ€”$1K-$2K per diagnosis)

---

### At-Risk Population Direct-to-Consumer Campaign

**Goal**: Reach Undiagnosed Symptomatic Patients (Self-Refer for Testing)

**Target Audience**:

- **Early COPD patients** (diagnosed with COPD age <50â€”unusual, should always check for AATD, but 70% of physicians don't)
- **Unexplained liver disease** (elevated LFTs, no obvious causeâ€”alcohol negative, hepatitis negative, AATD possible)
- **Family history** (know relative has "lung/liver problems," don't know AATD, suspect geneticâ€”"runs in family")

**Marketing Campaign**:

- **Digital ads**: Google ("COPD under 50," "genetic lung disease"), Facebook (target age 30-60, interests: lung health, ancestry, genetics)
- **Landing page**: "Could You Have Alpha-1?" (quiz: early COPD, liver problems, family historyâ€”if 2+ yes, "Get tested for $25")
- **Order kit**: Mail-in swab, $25 (Foundation subsidizes $175, patient pays shipping + small feeâ€”psychological commitment, reduces no-shows)

**Expected Volume**:

- Digital ads reach: 1M impressions/year ($50K ad spendâ€”$0.05/impression)
- Click-through: 1% (10,000 visitors to landing page)
- Conversion: 5% (500 order kitsâ€”most screen themselves out, only high-suspicion order)
- Diagnostic yield: 30-40% (family history + symptoms = enriched population, higher than 10% general population)
- New diagnoses: 150-200/year (500 kits Ã— 35% positive)

**Economics**:

- Ad spend: $50K/year
- Kit subsidies: 500 kits Ã— $175 = $87.5K/year
- Genetic counseling: $50K/year (1 FTE part-timeâ€”handle positive results)
- **Total cost**: $187.5K/year (150-200 diagnosesâ€”$940-$1,250/diagnosis, cost-effective)

---

## Cascade Screening Strategy

### Family-Based Diagnosis Amplification

**Every Diagnosis = Opportunity to Find 3-5 More**:

- Index patient diagnosed â†’ test siblings (find 0.5 on average)
- Index patient diagnosed â†’ test parents (confirm inheritance, find undiagnosed parentâ€”rare but happens, 0.1 on average)
- Index patient diagnosed â†’ test children if patient has kids (find 0.5-1 on average if partner is carrier)
- **Total cascade potential**: 1 index patient â†’ 1-2 additional diagnoses (doubles impact of every diagnosis program)

---

### Operationalizing Cascade Screening

**Step 1: Index Patient Education** (At Time of Diagnosis)

- Genetic counselor explains inheritance (draw pedigreeâ€”show who is at risk)
- Provide family testing kits (5 kitsâ€”"Mail these to your siblings, parents," pre-paid return envelopes)
- Follow-up (30 days laterâ€”"Did your family test? Need more kits?")

**Step 2: Family Outreach**

- Index patient contacts family ("I was diagnosed with genetic condition, you should get testedâ€”here's free kit")
- Some families reluctant (stigma, denial, fearâ€”not all participate)
- Foundation offers alternatives (family member can call Foundation directlyâ€”genetic counselor explains, answers questions, sends kit)

**Step 3: Results & Repeat**

- Positive results â†’ new index patient (becomes their own indexâ€”start cascade with their family)
- Exponential potential (1 patient â†’ 2 diagnoses â†’ 4 diagnoses â†’ 8 diagnosesâ€”pyramid effect if compliance high)

**Compliance Challenge**:

- Only 30-50% of at-risk family members complete testing (despite free kitsâ€”anxiety, procrastination, family dynamics)
- Foundation strategies to improve: Reminder calls, family education webinars ("Why Your Family Should Test"), testimonials from diagnosed patients

---

## Economics & ROI

### Cost Per Diagnosis by Strategy

**Ranked by Cost-Effectiveness**:

1. **23andMe Data Mining**: $13/diagnosis ($400K one-time / 30,000 diagnosesâ€”cheapest, but one-time opportunity)
2. **Cascade Screening**: $1,000-$2,000/diagnosis ($500K-$1M/year / 500 diagnosesâ€”highly efficient, sustainable)
3. **Invitae Panel Addition**: $20-$40/diagnosis ($100K-$200K support / 5,000 diagnosesâ€”very efficient, high volume)
4. **At-Home DTC Campaign**: $940-$1,250/diagnosis ($187.5K/year / 150-200 diagnosesâ€”moderate cost, targets symptomatic)
5. **Quest Reflex Testing**: $67-$100/diagnosis ($100K/year / 1,500 diagnosesâ€”clinical setting, physician-driven)

**For Comparison, Traditional Diagnosis Costs**:

- Symptomatic patient diagnosed via pulmonologist: $5,000-$10,000 (physician visits, imaging, multiple tests, specialist referrals before diagnosis)
- **All genetic testing strategies are 5x-100x more cost-effective than traditional route**

---

### 10-Year Projection: From 10% to 50% Diagnosed

**Current State**:

- 100,000 US AATD patients (estimated)
- 10,000 diagnosed (10%)
- 90,000 undiagnosed (90%)

**Foundation's 10-Year Goal**: Increase to 50,000 diagnosed (50% diagnosis rate)

**Pathway to 40,000 New Diagnoses**:

- **23andMe retrospective**: 30,000 (Year 1â€”one-time windfall)
- **23andMe prospective**: 20,000 (Years 2-10â€”2,000/year Ã— 10 years)
- **Invitae ongoing**: 50,000 (Years 1-10â€”5,000/year Ã— 10 years)
- **Cascade screening**: 50,000 (Years 1-10â€”amplifies every diagnosis, adds 50% to all programs)
- **Other strategies**: 20,000 (Quest, DTC, AncestryDNA, GeneDxâ€”smaller contributions)
- **Total**: 170,000 diagnosed over 10 years (accounts for duplicates, natural growth, reduced undiagnosed pool as denominator shrinks)

**Realistic 10-Year Outcome**: 50,000-70,000 diagnosed (50-70% diagnosis rateâ€”up from 10%, transformational)

---

### Investment Required

**Year 1** ($600K-$900Kâ€”launch partnerships):

- 23andMe pilot + rollout: $400K-$500K (one-time)
- Invitae partnership setup: $100K-$200K (implementation + physician education)
- Cascade screening program: $100K-$200K (first 200 index patients Ã— $500-$1K)

**Years 2-5** ($1M-$1.5M/yearâ€”scale programs):

- 23andMe prospective: $50K-$100K/year (ongoing support)
- Invitae support: $100K-$200K/year (CME, specialist network, annual optimization)
- Cascade screening: $500K-$1M/year (scale to 1,000 index patients/year)
- DTC campaigns: $187.5K/year (ads + kits)
- Quest/LabCorp: $100K/year (reflex testing support)
- AncestryDNA, GeneDx, others: $200K/year (expand partnerships)

**Years 6-10** ($1.5M-$2M/yearâ€”mature programs):

- All programs running at scale (efficiency improves, cost per diagnosis decreases)
- 10,000-15,000 new diagnoses/year (steady stateâ€”majority of undiagnosed now identified, incremental diagnoses from new births, immigration, etc.)

**Total 10-Year Investment**: $12M-$18M (identifies 150,000 patientsâ€”$80-$120/diagnosis, incredibly cost-effective)

---

## Implementation Roadmap

### Year 1: Launch Tier 1 Partnerships

**Q1-Q2: 23andMe Negotiation**

- Foundation initiates partnership discussions (research teamâ€”draft proposal, estimate patient yield, outline responsibilities)
- 23andMe runs pilot analysis (100-500 customersâ€”test notification messaging, measure response)

**Q3: 23andMe Pilot**

- Email 500 customers (measure click-through, confirmation, registry enrollment)
- Refine messaging ("Your test showed Alpha-1" vs. "Important genetic finding"â€”optimize)

**Q4: 23andMe Full Rollout**

- Email 30,000-60,000 customers (largest AATD diagnosis event in historyâ€”prepare infrastructure, genetic counselors, specialist network, PR)

---

### Year 2: Expand to Clinical Testing

**Q1: Invitae Partnership Launch**

- Invitae adds SERPINA1 to all panels (software updateâ€”5M tests/year now check AATD)
- Foundation launches CME course (educate 5,000 physiciansâ€”"Interpreting AATD Results")

**Q2-Q4: Other Clinical Labs**

- GeneDx adds AATD to rare disease panels (500K tests/year)
- Quest develops reflex testing protocol (simplify orderingâ€”double testing rate)
- LabCorp follows Quest (second-mover advantageâ€”learn from Quest's rollout)

---

### Year 3-5: Scale & Optimize

**Year 3**:

- AncestryDNA health pilot (AATD first health reportâ€”potential 20,000 diagnoses)
- Cascade screening scales (1,000 index patients/yearâ€”500 additional diagnoses from families)

**Year 4-5**:

- International expansion (partner with consumer genomics companies in Europeâ€”UK Biobank, German genomics, reach 500K AATD patients globally)
- Rare variant database (partner with Mayoâ€”sequence 10,000 AATD patients, identify all SERPINA1 variants, improve diagnostic accuracy)

---

## Summary

**Genetic Testing Partnerships = Foundation's Highest-Impact Diagnosis Strategy**:

- âœ… **10x Diagnosis Rate**: From 10% (10,000 diagnosed) to 50-70% (50,000-70,000) in 10 years
- âœ… **Cost-Effective**: $80-$120/diagnosis (vs. $5K-$10K traditionalâ€”50x more efficient)
- âœ… **Scalable**: Consumer genomics (50M+ databases), clinical testing (5M+/year)â€”sustainable pipeline
- âœ… **Proactive**: Catch patients before symptoms (genetic-first, not symptom-firstâ€”prevent lung damage)

**Priority Partnerships**:

1. **23andMe** (30,000-60,000 diagnoses Year 1â€”largest single impact)
2. **Invitae** (5,000/year ongoingâ€”highest annual volume)
3. **Cascade Screening** (doubles every other strategyâ€”force multiplier)

**10-Year Investment**: $12M-$18M total (identifies 150,000 patientsâ€”transforms AATD from 90% undiagnosed to majority diagnosed)

**"Find them before symptoms, save them from damage."**

---

**Explore Genetic Testing Partnership Opportunities**

**Mark Egly Foundation Genetic Testing Program**
ðŸ“§ Email: testing@markeglyfoundation.org
ðŸ“ž Phone: (XXX) XXX-XXXX
ðŸŒ Website: MarkEglyFoundation.org/GetTested

---

**Approved by**: Board of Directors, Scientific Advisory Board
**Effective Date**: January 1, 2026
**Review Date**: Annually
**Version**: 1.0

---

_"Test early, treat early, save lives."_

**â€” Mark Egly Foundation**
